Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets

This article was originally published in Scrip

Executive Summary

Amgen will pay $415 million to enhance the Thousand Oaks, California-based biotechnology powerhouse's drug discovery and development capabilities through the acquisition of deCODE Genetics, nearly three years after the Icelandic genome sequencer emerged from bankruptcy (scripintelligence.com, 22 January 2010).

You may also be interested in...



Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier

Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.

Amgen Rebuilt R&D Platform To Focus On Speed And Access

The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs. 

Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast

Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC019699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel